

# Effects of astaxanthin on the protection of muscle health (Review)

SOK KUAN WONG, SOELAIMAN IMA-NIRWANA and KOK-YONG CHIN

Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia,  
Jalan Ya'acob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia

Received February 3, 2020; Accepted June 17, 2020

DOI: 10.3892/etm.2020.9075

**Abstract.** Sarcopenia refers to the involuntary and generalized deterioration of skeletal muscle mass and strength, which may lead to falls, frailty, physical disability, loss of independence, morbidity and mortality. The majority of molecular and

cellular changes involved in the degeneration of muscle tissues are mediated by oxidative stress. Therefore, astaxanthin may act as a potential adjunct therapy for sarcopenia owing to its antioxidant activity. The present review examines the effects of astaxanthin on the promotion of skeletal muscle performance and prevention of muscle atrophy and the potential mechanisms underlying these effects. The available evidence till date was retrieved from PubMed and Medline electronic databases. The present review reported the beneficial effects of astaxanthin in preventing muscle degeneration in various animal models of sarcopenia. In humans, the effects of astaxanthin in combination with other antioxidants on muscle health are mixed, wherein positive and negligible effects were reported. Mechanistic studies revealed that astaxanthin promotes muscle health by reducing oxidative stress, myoblast apoptosis and proteolytic pathways while promoting mitochondria regeneration and formation of blood vessels. Thus, astaxanthin is a potential therapeutic agent for sarcopenia but its effects in humans require further validation.

*Correspondence to:* Dr Kok-Yong Chin, Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Ya'acob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia  
E-mail: chinkokyong@ppukm.ukm.edu.my

**Abbreviations:** 1-RM, one repetition maximum; 4-HNE, 4-hydroxy-2-nonenal; 5'-AMPK, 5'-adenosine monophosphate-activated protein kinase; 8-OHdG, 8-hydroxy-2'-deoxyguanosine;  $\alpha$ -SMA, alpha-smooth muscle actin; Akt, protein kinase B; ANG-1, angiotensin 1; AOPP, advanced oxidation protein products; ARE, antioxidant responsive elements; AST, aspartate aminotransferase; C/F, capillary-to-fibre; CAF, capillary number per fibre; CAT, catalase; CK, creatine kinase; CSA, cross-sectional area; eNOS, endothelial nitric oxide synthase; FCSA, fibre cross-sectional area; FDA, Food and Drug Administration; Flt-1, FMS-like tyrosine kinase 1; FNDC5, fibronectin type III domain-containing protein 5; FoxO, Forkhead Box O; FoxO3a, Forkhead box class O 3a; FRAP, ferric-reducing activity of plasma; GCLC, glutamate-cysteine ligase catalytic subunit; GCLM, glutamate-cysteine ligase modifier subunit; GPx, glutathione peroxidase; HbA1c, glycated haemoglobin; HIF-1 $\alpha$ , hypoxia inducible factor-1 alpha; HMOX-1, heme oxygenase (decycling) 1; HOMA-IR, homeostatic model assessment of insulin resistance; IGF-1, insulin growth factor-1; KDR, kinase insert domain-containing receptor; Keap1, Kelch-like ECH-associated protein 1; MDA, malondialdehyde; MDF, mean dynamic force; MIF, mean isometric force; MVC, maximal voluntary contraction; MPO, myeloperoxidase; mTOR, mammalian target of rapamycin; NEFA, non-esterified fatty acids; NQO-1, NAD(P)H quinone dehydrogenase; Nrf2, nuclear factor erythroid 2-related factor 2; P70S6K, p70 ribosomal protein S6 kinase; PGC-1 $\alpha$ , peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PI3K, phosphatidylinositol-3-kinase; RONS, reactive nitrogen species; ROS, reactive oxygen species; SDH, succinate dehydrogenase; SOD, superoxide dismutase; TBARS, thiobarbituric acid-reactive substances; TEAC, trolox-equivalent antioxidant capacity; TGF- $\beta$ 1, transforming growth factor-beta 1; Tie-2, tyrosine kinase with Ig and EGF homology domains 2; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labelling; VEGF, vascular endothelial growth factor

**Key words:** astaxanthin, mitochondria, muscle atrophy, oxidative stress, sarcopenia

## Contents

1. Introduction
2. Literature search
3. Effects of astaxanthin on skeletal muscle: Evidence from *in vivo* studies
4. Effects of astaxanthin on skeletal muscle: Evidence from human studies
5. The mechanism of action of astaxanthin
6. Perspectives and conclusion

## 1. Introduction

Sarcopenia is a condition characterized by a progressive reduction in skeletal muscle mass and strength, which affects balance, mobility, overall physical performance and quality of life (1). Risk factors for sarcopenia include increased age, being of the male sex, malnutrition and a sedentary lifestyle (2). Primary sarcopenia is often age-related without apparent underlying causes, whereas secondary sarcopenia is associated with one or more causes (1). Major co-morbidities associated with sarcopenia are obesity, osteoporosis and type 2 diabetes mellitus (3). A meta-analysis of 35 studies showed that the global prevalence of sarcopenia is 10% in

men and women, and the prevalence is higher in non-Asian countries than in Asian countries (4). It is estimated that the cost of hospitalisation associated with sarcopenia was approximately \$40.4 billion USD in the United States, with an average cost of \$260 USD per individual (5). Sarcopenia has also become a topic of interest in recent years, as an increasing proportion of the global population being of advanced age is projected to triple between 2017 and 2050 (6). The development of prophylactic and therapeutic strategies for sarcopenia may therefore become imperative to ensure healthy ageing. It is also noteworthy that there are no US Food and Drug Administration (FDA)-approved drugs for the treatment of sarcopenia (7). Understanding the pathogenesis of sarcopenia will be important in the design of prophylactic and therapeutic strategies for the disease. Oxidative stress, inflammation, impairment of mitochondrial function, increased protein turnover and capillary regression can result in the loss of skeletal muscle mass and ultimately sarcopenia (8-11). Previous studies have demonstrated that the administration of antioxidants reduced the level of oxidative stress during exercise (12) and the level of muscle atrophy (13). These findings suggest a potential role for antioxidants in reversing sarcopenia.

Astaxanthin is a fat-soluble, naturally occurring xanthophyll carotenoid identified in numerous organisms, such as microalgae, crustaceans and fish (such as salmon and trout) (14). Astaxanthin is a powerful antioxidant that effectively scavenges free radicals, quenches singlet oxygen, enhances antioxidant activities and reduces oxidative stress (15). The nutraceutical applications of astaxanthin previously reported include anti-inflammatory (16), anti-cancer (17) and anti-diabetic (18) and it has also been reported to have gastro- (19), hepato- (20), neuro- (21), cardio- (22), ocular- (23) and skin-protective (24) properties.

A recent review summarised the potential application of astaxanthin as a dietary supplement in exercising humans. The author concluded that there was an improvement of exercise metabolism, performance and recovery following astaxanthin supplementation (25). In addition, an *in vitro* study by Yu *et al* (26) demonstrated that incubation of the mouse myoblast C2C12 cell line with astaxanthin (5  $\mu$ M) during heat stress (43°C) prevented adverse changes to the tubular mitochondrial structure and mitochondrial membrane potential, as well as reactive oxygen species (ROS) production. Thus, astaxanthin may have a potential application in preventing muscle injury and degeneration. In the present review, the health-promoting effects of astaxanthin on the skeletal muscle in animal models and humans are presented. The molecular mechanisms underlying the health benefits of astaxanthin in reversing adverse muscle changes are also highlighted.

## 2. Literature search

Evidence acquisition was conducted between February 1st and February 29th 2020 using PubMed and Medline electronic databases. The key words used to perform the search were 'astaxanthin AND (sarcopenia OR muscle)'. All *in vitro*, *in vivo* and human studies detailing the effects of astaxanthin and its underlying mechanisms on muscle health were extracted. A total of 20 related studies are included in the present review.

## 3. Effects of astaxanthin on skeletal muscle: Evidence from *in vivo* studies

The effects of astaxanthin on skeletal muscle have been explored *in vivo* (Table I). Recently, Aoi *et al* (27) compared the effects of three different forms of astaxanthin on endurance performance in 8-week-old ICR mice. Astaxanthin derived from *Haematococcus pluvialis* (esterified form), synthetic astaxanthin (non-esterified form) or astaxanthin derived from *Phaffia rhodozyma* (non-esterified form) was provided to the animals in their diet at a dose of 0.02% (w/w) for five weeks. The animals were subjected to treadmill exercise with a running speed of 25 m/min for the assessment of endurance and their running time to exhaustion was measured. The study indicated that animals fed with astaxanthin from *H. pluvialis* had the longest running time to exhaustion among the experimental groups (27). Long-term effects of astaxanthin supplementation were also evaluated using an exercised animal model. Adult male Wistar rats were administered mineral oil (vehicle) or astaxanthin (1 mg/kg) five days per week for 45 days. The animals treated with astaxanthin had a higher elapsed time until exhaustion in a forced-swimming activity when compared with exercised animals without treatment (28).

In another study, Kawamura *et al* (29) investigated the effects of astaxanthin alone, or in combination with other antioxidants ( $\beta$ -carotene and resveratrol), on muscle atrophy in 7-week-old male ICR mice. The knee and ankle joints of one hindlimb were fixed with a cast to induce muscle atrophy and removed after three weeks. After cast removal, the animals were fed a basal diet enriched with astaxanthin,  $\beta$ -carotene, resveratrol or a mixture of the three antioxidants for two weeks. The animals given a basal diet with astaxanthin alone or a mixture of the three antioxidants had significantly higher soleus muscle weight when compared to the normal animals (29).

An animal model of hindlimb unloading was also used to assess the effects of astaxanthin on atrophied soleus muscle. Kanazashi *et al* (30) performed hindlimb unloading on adult male Wistar rats for 7 days by suspending the tail, to prevent weight bearing of the hindlimb on the floor or contact with the sides of the cage. Astaxanthin was administered orally at 50 mg/kg twice per day for 7 days. Astaxanthin was demonstrated to prevent the changes caused by hindlimb unloading, indicated by the preserved capillary-to-fibre (C/F) ratio, capillary number per fibre (CAF), capillary volume and capillary diameter of the treated group. As astaxanthin supplementation alone was beneficial in preventing capillary regression, while exerting minimal impact on muscle mass, the same group of researchers hypothesized that a combination of astaxanthin and intermittent loading would work synergistically on the prevention of muscle atrophy and capillary regression during hindlimb unloading. In the subsequent study, the animals were subjected to hindlimb unloading followed by the release of the suspension device to allow for normal cage activity for one hour daily in darkness. The study duration was extended to two weeks. As expected, the results indicated that intermittent unloading combined with astaxanthin ameliorated both soleus muscle atrophy and capillary regression in the hindlimb unloaded animals (31). A recent study was conducted to

Table I. Summary of the findings of studies exploring the effects of astaxanthin on skeletal muscle in animals.

Animal species/strain	Experimental groups	Treatment period	Summary of findings	Author (Refs.)
ICR mice (n=40; 8 weeks old)	i) control ii) astaxanthin (0.02% w/w) from <i>Haematococcus pluvialis</i> iii) synthetic astaxanthin (0.02% w/w) iv) astaxanthin (0.02% w/w) from <i>Phaffia rhodozyma</i>	5 weeks	Among all the experiment groups: Animals fed with astaxanthin from <i>Haematococcus pluvialis</i> had the longer running time to exhaustion and higher 5'-AMPK content in skeletal muscle.	Aoi <i>et al</i> (27), 2018
Male Wistar rats (n=24; age not mentioned)	i) rested control ii) rested control + astaxanthin (1 mg/kg; 5 days/week; oral) iii) exercise iv) exercise + astaxanthin (1 mg/kg; 5 days/week; oral)	45 days	Compared to the rested control group: Astaxanthin increased elapsed time until exhaustion in a forced-swimming activity, TEAC and FRAP capacity. Compared to the exercised group: Astaxanthin increased TEAC and FRAP capacity and lowered TBARS and protein carbonyl content.	Polotow <i>et al</i> (28), 2014
ICR mice with muscle atrophy (n=44; 7 weeks old)	i) normal ii) astaxanthin (0.06% w/w) iii) $\beta$ -carotene (0.06% w/w) iv) resveratrol (0.06% w/w) v) mixture of antioxidants (astaxanthin, $\beta$ -carotene, resveratrol; 0.02% w/w each)	2 weeks	Compared to the normal group: Astaxanthin increased relative soleus weight. A mixture of antioxidants increased relative soleus weight, mTOR phosphorylation level, P70S6K phosphorylation level and reduced carbonylated protein levels.	Kawamura <i>et al</i> (29), 2019
Male Wistar rats (n=24; age not mentioned)	i) control ii) control + astaxanthin (50 mg/kg; twice per day; oral) iii) hindlimb unloading iv) hindlimb unloading + astaxanthin (50 mg/kg; twice per day; oral)	7 days	Compared to the hindlimb unloaded group: Astaxanthin increased C/F ratio, CAF, capillary volume, capillary diameter and HIF-1 $\alpha$ , VEGF, Flt-1, KDR, ANG-1 and Tie-2 levels but reduced ROS production and SOD-1 protein.	Kanazashi <i>et al</i> (30), 2013
Male Sprague-Dawley rats (n=35; 10 weeks old)	i) control ii) hindlimb unloading iii) hindlimb unloading + astaxanthin (50 mg/kg; twice per day; oral) iv) hindlimb unloading + intermittent loading v) hindlimb unloading + astaxanthin (50 mg/kg; twice per day; oral) + intermittent loading	2 weeks	Compared to the hindlimb unloaded group: Astaxanthin increased capillary volume, capillary diameter, C/F ratio and eNOS, PGC-1 $\alpha$ and VEGF levels and SDH activity but decreased ROS production and SOD-1 protein levels. Astaxanthin + intermittent loading increased soleus mass, FCSA, capillary volume, capillary diameter, C/F ratio and CAF, eNOS, PGC-1 $\alpha$ and VEGF levels and SDH activity but decreased ROS production and SOD-1 protein in a greater extent.	Kanazashi <i>et al</i> (31), 2014

Table I. Continued.

Animal species/strain	Experimental groups	Treatment period	Summary of findings	Author (Refs.)
Male Sprague-Dawley rats (n=30; 10 weeks old)	i) control ii) hindlimb unloading iii) hindlimb unloading + astaxanthin (50 mg/kg; twice per day; oral) iv) hindlimb unloading + electrical stimulation v) hindlimb unloading + astaxanthin (50 mg/kg; twice per day; oral) + electrical stimulation	1 week	Compared to the hindlimb unloaded group: Astaxanthin increased SDH activity, C/F ratio and PGC-1 $\alpha$ level and reduced ubiquitination of proteins, ROS production and SOD-1 protein. Astaxanthin and electrical stimulation synergistically increased FCSA, absolute and relative soleus muscle mass, phosphorylation of FoxO3a, SDH activity, C/F ratio, PGC-1 $\alpha$ as well as reducing ubiquitination of proteins, ROS production and SOD-1 protein.	Kanazashi <i>et al</i> (32), 2019
Male Wistar rats (n=27; 8 weeks old)	i) control ii) hindlimb unloading iii) hindlimb unloading + astaxanthin (0.04% w/w)	3 weeks	Compared to the hindlimb unloaded group: Astaxanthin increased relative soleus muscle mass and FCSA, and reduced apoptotic nuclei and of protein ubiquitination levels.	Yoshihara <i>et al</i> (33), 2017
Male Wistar rats (n=49; 8 weeks old)	i) control ii) hindlimb unweighting iii) hindlimb unweighting + intermittent reloading iv) hindlimb unweighting + intermittent reloading + astaxanthin (0.04% w/w) v) hindlimb unweighting + intermittent reloading + heat stress vi) hindlimb unweighting + intermittent reloading + astaxanthin (0.04% w/w) + heat stress	3 weeks	Compared to the hindlimb unweighting group: A combination of intermittent reloading, astaxanthin supplementation and heat stress increased soleus muscle mass, soleus cross-sectional area and satellite cell numbers.	Yoshihara <i>et al</i> (34), 2018
Male Wistar rats (n=23; 14 weeks old)	i) placebo diet ii) astaxanthin (0.04%) iii) astaxanthin (0.2%) iv) immobilization + placebo diet v) immobilization + astaxanthin (0.04%) vi) immobilization + astaxanthin (0.2%)	24 days	Compared to the immobilization + placebo diet group: Astaxanthin reduced the percentage of immobilized muscle, SOD level and calpain and ubiquitin expression in the atrophied plantaris muscle.	Shibaguchi <i>et al</i> (38), 2016
Male Wistar rats (n=28; 7 weeks old)	i) control ii) control + astaxanthin (100 mg/kg, daily; oral) iii) joint immobilization iv) joint immobilization + astaxanthin (100 mg/kg, daily; oral)	3 weeks	Compared to the joint immobilization group: Astaxanthin lowered the collagen fibre area, transforming growth factor- $\beta$ 1, $\alpha$ -smooth muscle actin, ROS production and SOD-1.	Maetzawa <i>et al</i> (39), 2017

Table I. Continued.

Animal species/strain	Experimental groups	Treatment period	Summary of findings	Author (Refs.)
Male C57BL/6J mice (6-week-old)	i) normal chow ii) normal chow + astaxanthin iii) high-fat diet (60%) iv) high-fat diet (60%) + astaxanthin (0.02%)	24 weeks	Compared to high-fat diet group: Astaxanthin enhanced exercise tolerance and prevented metabolic syndrome.	Nishida <i>et al</i> (40), 2020
Broiler chicks (n=32; 15 days old)	i) thermo-neutral temperature + basal diet ii) thermo-neutral temperature + basal diet supplemented with 0.15% Panaferd-P (30 ppm astaxanthin) iii) high temperature + basal diet iv) high temperature + basal diet supplemented with 0.15% Panaferd-P (30 ppm astaxanthin)	28 days	Compared to the basal diet group: Astaxanthin increased breast and leg muscle redness and yellowness; ameliorated high ambient temperature-induced decrease in muscle redness. Astaxanthin decreased breast muscle MDA concentration under both thermo-neutral and high ambient temperature conditions.	Inoue <i>et al</i> (41), 2019
Female C57BL/6 mice (n=27; 7 weeks old)	i) rested control ii) intense exercise iii) intense exercise + astaxanthin (0.02% w/w)	3 weeks	Compared to the intense exercise group: Astaxanthin decreased the expression of 4-HNE-modified protein, production of 8-OHdG, MPO activity and CK activity.	Aoi <i>et al</i> (52), 2003
Male C57BL/6 mice (n=40; 7 weeks old)	i) sedentary control ii) swimming control iii) swimming + astaxanthin (5 mg/kg, 5 days/week; oral) iv) swimming + astaxanthin (15 mg/kg; 5 days/week; oral) v) swimming + astaxanthin (30 mg/kg; 5 days/week; oral)	14 weeks	Compared to the swimming control group: Astaxanthin decreased GPx, CAT, MDA and CK levels but increased SOD level Astaxanthin downregulated Nrf2 and Nrf2-dependent enzymes [Keap1, glutamate-cysteine ligase modifier subunit, glutamate-cysteine ligase catalytic subunit, NAD(P)H quinone dehydrogenase and heme oxygenase (decycling) 1].	Zhou <i>et al</i> (53), 2019
ICR mice (n=32; 7 weeks old)	i) rested control ii) rested control + astaxanthin (0.02% w/w) iii) exercise iv) exercise + astaxanthin (0.02% w/w)	2 weeks	Compared to the exercised group: Astaxanthin decreased plasma non-esterified fatty acids, increased intermuscular pH, PGC-1 $\alpha$ , cytochrome c and fibronectin type III domain-containing protein 5.	Liu <i>et al</i> (63), 2014

For the studies without the detail on frequency of administration, astaxanthin was supplemented into the basal diet, thus daily administration would be expected. 4-HNE, 4-hydroxy-2-nonenal; 5'-AMPK, 5'-adenosine monophosphate-activated protein kinase; 8-OHdG, 8-hydroxy-2'-deoxyguanosine; ANG-1, angiopoietin 1; C/F, capillary-to-fibre; CAF, capillary number per fibre; CAT, catalase; CK, creatine kinase; eNOS, endothelial nitric oxide synthase; FCSEA, fibre cross-sectional area; Flt-1, FMS-like tyrosine kinase 1; FoxO3a, Forkhead box class O 3a; FRAP, ferric-reducing activity of plasma; GPx, glutathione peroxidase; HIF-1 $\alpha$ , hypoxia inducible factor-1 alpha; KDR, kinase insert domain-containing receptor; Keap1, Kelch-like ECH-associated protein 1; MDA, malondialdehyde; MPO, myeloperoxidase; mTOR, mammalian target of rapamycin; Nrf2, nuclear factor erythroid 2-related factor 2; P70S6K, p70 ribosomal protein S6 kinase; PGC-1 $\alpha$ , peroxisome proliferator-activated receptor gamma coactivator 1-alpha; ROS, reactive oxygen species; SDH, succinate dehydrogenase; SOD, superoxide dismutase; TBARS, thiobarbituric acid-reactive substances; TEAC, trolox-equivalent antioxidant capacity; Tie-2, tyrosine kinase with Ig and EGF homology domains 2; VEGF, vascular endothelial growth factor.

evaluate the effects of a combined therapy of astaxanthin and electrical stimulation on muscle atrophy using hindlimb unloaded rats. For electrical stimulation, calf muscles of the rats were electrically stimulated using a surface electrode (diameter: 1 cm, frequency: 100 Hz) for 240 sec/day. Treatment with astaxanthin alone increased the C/F ratio. The combined therapy was more efficient than astaxanthin alone in reversing the adverse changes due to hindlimb unloading. The combination of astaxanthin and electrical stimulation increased absolute soleus muscle mass and fibre cross-sectional area (FCSA) (32). Another group of researchers reported that dietary astaxanthin supplementation prior to and during hindlimb unloading suppressed soleus muscle atrophy. Compared to the animals subjected to hindlimb unloading without treatment, astaxanthin supplementation caused higher muscle weight and FCSA in the soleus muscle (33). A comprehensive study done by Yoshihara *et al* (34) illustrated the effects of a combination of astaxanthin supplementation, heat stress and intermittent reloading on the hindlimb unweighted rats. Hindlimb unloading was conducted as aforementioned, whereby the tail was immobilized in a cast, allowing the animals to move only using their front feet. The animals were placed in a heat chamber at 41.0–41.5°C for 30 min. Intermittent reloading was performed during the heating phase for one hour every other day to allow daily activities. Astaxanthin was mixed into their basal diet at 0.04% w/w. The combination of dietary astaxanthin, heat treatment and intermittent reloading resulted in higher soleus muscle weight and cross-sectional area in the hindlimb unloaded animals (34).

Hindlimb immobilization is another method to induce muscle atrophy. Immobilization refers to holding a joint or bone in place with a cast to prevent its movement, thus inducing muscle contracture and atrophy (35,36). In contrast, the rodents are in a head-down position to simulate weightlessness for hindlimb unloading (37). In an *in vivo* study, three groups of male Wistar rats were given either a placebo diet, or a 0.04 or 0.2% astaxanthin diet for 24 days. At day 14, hindlimb muscle immobilization was introduced to the rats in the maximum plantar flexion position with a plaster cast. It was demonstrated that the degree of muscle atrophy was lessened in the rats fed with a diet supplemented with astaxanthin (38). Similarly, Maezawa *et al* (39) introduced joint immobilization to 7-week-old male Wistar rats using the same approach. Astaxanthin (100 mg/kg) was administered orally each day for three weeks (one week before and two weeks during ankle joint immobilization). The treatment of astaxanthin reduced FCSA in the rats with joint immobilization (39).

In high-fat diet fed male C57BL/6J mice, astaxanthin was shown to increase exercise endurance. The astaxanthin-treated mice were able to run for a longer distance than the untreated mice when subjected to daily exercise using a treadmill and wheel. Astaxanthin also increased glucose tolerance after regular daily training, along with other metabolic syndrome parameters [fasting blood glucose, insulin, homeostatic model assessment of insulin resistance (HOMA-IR), glycated haemoglobin (HbA1c), systolic blood pressure, triglyceride and total cholesterol were reduced] (40).

The impact of astaxanthin supplementation on meat colouration in chickens has been evaluated. Using 15-day-old Broiler chicks as an animal model, Inoue *et al* (41) randomly

assigned the chicks to one of the four groups using a 2x2 factorial design. The two main variables in this study were diet [basal diet or basal diet enriched with 0.15% Panaferd-P (containing 30 ppm astaxanthin)] and ambient temperature [thermo-neutral temperature (25±1°C) or high temperature (35±1°C)]. It was revealed that a diet containing Panaferd-P increased muscle carotenoid content, redness and yellowness of the skeletal muscle (meat) in the broiler chicks under the condition of thermo-neutral and high ambient temperature (41). Meat colour determines meat quality (42). A decrease in muscle redness might be a consequence of an alteration in muscle myoglobin concentration (the main protein responsible for meat colour), heat stress and feed restriction (42,43). Meanwhile, a reduction in muscle yellowness is an indicator for decreasing carotenoid (astaxanthin, adonixanthin, canthaxanthin, adonirubin, lutein and zeaxanthin) accumulations in muscle. Hence, the increases in muscle redness and yellowness indicated quality improvement of the meat (41).

#### 4. Effects of astaxanthin on skeletal muscle: Evidence from human studies

Limited studies have been conducted in humans to test the effects of astaxanthin on muscle, particularly in the aspects of muscle injury/damage and muscle strength (Table II). The effects of astaxanthin on muscle injury were studied among resistance-trained men (n=20, aged 25.1±1.6 years). The subjects were equally divided into the placebo (administered 1,732 mg safflower oil) or astaxanthin (administered 4 mg astaxanthin and 480 mg lutein) groups. After three weeks of assigned treatments, the participants were subjected to eccentric exercise (10 sets of 10 repetitions at 85% of one repetition maximum) and followed through 96 h post-exercise. The parameters measured in this study include muscle soreness, creatine kinase (CK) activity and muscle performance. A similar response in these variables was noted for both groups, reiterating that astaxanthin supplementation exerted negligible effects on skeletal muscle injury following eccentric loading (44). Another human study demonstrated the effects of astaxanthin supplementation (4 mg) for 90 days on muscle damage, oxidative stress and antioxidant capacity during soccer training in elite young soccer players. Treatment with astaxanthin did not change the levels of thiobarbituric acid-reactive substances (TBARS) and advanced oxidation protein products (AOPP) throughout this study. The CK and aspartate aminotransferase (AST) activities in serum were significantly increased with soccer training without treatment but were lowered with astaxanthin administration (45). In a randomized, double-blind, placebo-controlled study, Liu *et al* (46) examined a test formulation consisting of astaxanthin (12 mg), tocotrienol (10 mg) and zinc (6 mg) on building strength, endurance and mobility in exercise training among the elderly. A total of 42 elderly subjects (aged 65–85 years) were recruited, fed with test formulation or placebo for 4 months and trained with increasing intervals of incline walking for three months (three times weekly for 40–60 min). In this study, muscle strength was presented as maximal voluntary contraction (MVC) in an ankle dorsiflexion exercise, and the tibialis anterior muscle size was measured as cross-sectional area (CSA) using magnetic resonance imaging. The authors

Table II. Summary of the findings of studies exploring the effects of astaxanthin on skeletal muscle in humans.

Subjects	Groups	Treatment period	Findings	Author (Refs)
Resistance trained men (n=20; mean age, 25.1±1.6 years)	i) placebo (1,732 mg safflower oil) ii) astaxanthin [1,732 mg safflower oil + <i>haemotococcus</i> iii) algae extract (contains 4 mg astaxanthin and 480 mg lutein)]	3 weeks	No significant difference was observed in muscle soreness, CK, one repetition maximum concentric strength, mean isometric force and mean dynamic force (MDF) between the two groups.	Bloomer <i>et al</i> (44), 2005
Male elite soccer players (n=32, age not mentioned)	i) placebo ii) astaxanthin (4 mg)	90 days	No change in TBARS and AOPP levels between the two groups. In comparison with the placebo: Astaxanthin increased SOD activity after 2 h of soccer exercise. Astaxanthin lowered post-exercise CK and AST levels.	Djordjevic <i>et al</i> (45), 2012
Elderly men and women (n=42; aged 65-82 years)	i) exercise training + placebo (mean age: 72.2±5.2 years) ii) exercise training + astaxanthin (12 mg) + tocotrienol (10 mg) + zinc (6 mg) (mean age: 69.1±3.4 years)	4 months	Exercise training increased endurance (exercise time) and distance in 6 min walk in both groups. In comparison with a placebo: Astaxanthin treatment increased MVC and CSA.	Liu <i>et al</i> (46), 2018
Healthy young men (n=20)	i) exercise training (mean age: 20.8±0.3 years) ii) exercise training + antioxidants (catechin, astaxanthin, quercetin, glutathione and anthocyanin) (mean age: 21.4±0.4 years)	4 weeks	Maximum workload and duration of exercise were increased in both groups In the antioxidant group: Oxygen consumption and carbohydrate oxidation post-training were increased. A positive correlation was observed between maximum work-load and fat oxidation Serum insulin was decreased	Takami <i>et al</i> (47), 2019

AOPP, advanced oxidation protein products; AST, aspartate aminotransferase; CK, creatine kinase; CSA, cross-sectional area; MVC, maximal voluntary contraction; SOD, superoxide dismutase; TBARS, thiobarbituric acid-reactive substances.

identified a greater endurance in a 6-min walk upon exercise training in both experimental groups. The subjects administered astaxanthin formulation had higher MVC and CSA, indicating improved muscle strength and size as compared to the placebo-treated exercised subjects (46).

A recent study by Takami *et al.* (47) assessed whether foods containing antioxidants (such as catechin, astaxanthin, quercetin, glutathione and anthocyanin) could boost aerobic metabolism during exercise training. All participants were divided into two groups subjected to supervised cycling training for 30 min (three days per week) for four weeks with or without taking antioxidant-rich foods. Several observations were made in this study. The values of oxygen consumption and carbohydrate oxidation after training during rest and exercise conditions were significantly increased in the antioxidant group. A positive correlation was observed between fat oxidation during exercise and maximum workload after training. The magnitude of decrease in serum insulin level after training was higher in the antioxidant group as compared to the control group (47).

Overall, the evidence derived from *in vivo* studies suggested a beneficial effect of astaxanthin in preventing muscle degeneration. In humans, the effects of astaxanthin alone or in combination with other antioxidants on muscle health were heterogeneous, as both positive and negligible effects were reported.

## 5. The mechanism of action of astaxanthin

Understanding of the biological mechanisms underlying the decline in muscle strength and mass is of substantial importance in the search for potential therapeutic agents to prevent sarcopenia. The widely accepted mechanisms involved in muscle atrophy leading to pathogenesis of sarcopenia include induction of oxidative stress, impaired mitochondrial dynamics and functions, negative protein turnover (defined as a disproportionate decrease in muscle protein synthesis and/or an increase in muscle protein breakdown) as well as regression of the capillary network in skeletal muscle (39).

Oxidative stress exerts dual actions on skeletal muscle, whereby a low level of oxidative stress is beneficial while excessive oxidative stress is detrimental (48). Oxidative stress is closely associated with sarcopenia, which is largely attributed to the excessive yield of reactive oxygen and nitrogen species (RONS) during ageing, high-intensity exercise and disuse atrophy (49). An increase in ROS level inflicts direct alteration or damage on important macromolecules, such as lipids, proteins and nucleic acids, contributing to the loss of muscle mass and strength (50). The anti-oxidative properties of astaxanthin have been widely demonstrated by researchers, evidenced by reduction in various lipid peroxidation by-products, oxidative stress biomarkers and markers of muscle damage (51). An earlier animal study demonstrated that astaxanthin attenuated exercise-induced skeletal and cardiac muscle damage in 7-week-old female C57BL/6 mice. The animals were randomly assigned to three groups: Rested controls, intense exercise and intense exercise supplemented with dietary astaxanthin (0.02% w/w). Exercise acclimation (running on a motor-driven treadmill with running intensity increased from 5 to 28 m/min) performed for 10 min/day three times per week

for three weeks. At the end of the study, the exercise groups ran on a treadmill at 28 m/min until exhaustion. The data from this study showed that increases in 4-hydroxy-2-nonenal (4-HNE)-modified protein, 8-hydroxy-2'-deoxyguanosine (8-OHdG), plasma CK activity and myeloperoxidase (MPO) activity in the gastrocnemius and heart caused by exercise were attenuated by astaxanthin (52). Astaxanthin treatment was effective in lowering the concentrations of malondialdehyde (MDA) or TBARS, ROS and carbonylated protein in various animal models (28-32,38,39,41,53).

The complex endogenous antioxidant defence system, consisting of key antioxidant enzymes such as glutathione peroxidase (GPx), superoxide dismutase (SOD) and catalase (CAT), plays a crucial role in neutralizing damaging free radical species (54). High doses of astaxanthin (15 or 30 mg/kg) were shown to be effective in suppressing the levels of GPx, CAT and CK and raising SOD activity in plasma and muscle of mice after moderate-intensity swimming training (53). Another group of researchers pinpointed the reduction in SOD-1 expression in animals with muscle atrophy induced by hindlimb unloading treated with astaxanthin alone (30) or in combination with other interventions such as intermittent loading (31) or electrical stimulation (32). In line with these studies, a lowered SOD-1 level was also detected in two other studies using animals subjected to hindlimb immobilization-induced muscle atrophy (38,39). Astaxanthin supplementation also increased antioxidant capacity in the plasma, indicated by higher Trolox-equivalent antioxidant capacity (TEAC) levels and ferric-reducing activity of plasma (FRAP) capacity relative to the control animals (28).

At the molecular level, the signalling pathway involved in normalizing the disrupted balance between pro-oxidant and antioxidant levels is that of the nuclear factor erythroid 2-related factor 2 (Nrf2) (55). In the resting condition, Nrf2 assumes an inactive state by binding to Kelch-like ECH-associated protein 1 (Keap1) to cause its ubiquitination and degradation (56). Oxidative stress causes a conformational change in Keap1 by interfering in the interaction between Nrf2 and Keap1. Free Nrf2 is subsequently released, translocated into the nucleus and bound to antioxidant responsive elements (ARE) to allow transcription of genes that encode for detoxifying or antioxidant enzymes (56). The transcription of Nrf2 and Nrf2-dependent enzymes in the mouse heart during moderate-intensity swimming training were downregulated in astaxanthin-treated animals (53). In this context, it appears that either the lack of or excess of ROS and antioxidants elicited important pathological implications in skeletal muscle. An optimal amount of ROS and antioxidants may serve as an important factor in maximizing skeletal muscle performance.

The mitochondrial electron transport chain is the major site of ROS production in skeletal muscle, thus mitochondrial DNA is susceptible to oxidative damage by overwhelming ROS production, affecting mitochondrial homeostasis and function (57). Changes in mitochondrial membrane potential, reduction in mitochondrial energy production capacity, inhibition of mitochondrial oxygen consumption and reduction in mitochondrial biogenesis are common characteristics of mitochondrial dysfunction (58), which are (59). During physical activity, endothelial nitric oxide synthase (eNOS) is upregulated






Figure 1. The potential mechanism of action of astaxanthin in the prevention of sarcopenia. ANG-1, angiopoietin 1; eNOS, endothelial nitric oxide synthase; Flt-1, FMS-like tyrosine kinase 1; FoxO, Forkhead Box O; HIF-1 $\alpha$ , hypoxia inducible factor-1 alpha; KDR, kinase insert domain-containing receptor; mTOR, mammalian target of rapamycin; P70S6K, p70 ribosomal protein S6 kinase; PGC-1 $\alpha$ , peroxisome proliferator-activated receptor gamma coactivator 1-alpha; SDH, succinate dehydrogenase; Tie-2, tyrosine kinase with Ig and EGF homology domains 2; VEGF, vascular endothelial growth factor.

to increase nitric oxide production, which subsequently induces mitochondrial biogenesis and cell glucose uptake in skeletal muscle. Peroxisome proliferator-activated receptor gamma coactivator 1- $\alpha$  (PGC-1 $\alpha$ ) is a master regulator of mitochondrial biogenesis that regulates the genes involved in cellular energy metabolism (60,61). High levels of PGC-1 $\alpha$  are an indicator of improved aerobic metabolism and function of mitochondria (62). Using an exercised mouse model, Liu *et al* (63) suggested that astaxanthin accelerated lipid utilization in skeletal muscle and reduced intermuscular pH during aerobic exercise through elevation of PGC-1 $\alpha$ . Studies conducted by Kanazashi *et al* (31,32) identified a similar pattern to astaxanthin alone, astaxanthin with intermittent loading and astaxanthin with electrical stimulation retained mitochondrial biogenesis by raising PGC-1 $\alpha$  and eNOS expression in the soleus muscle of hindlimb unloaded mice. The total 5'-adenosine monophosphate-activated protein kinase (AMPK) content in skeletal muscle was also significantly augmented in the exercised animals fed with astaxanthin from *H. pluvialis* than the control group. These findings suggested that astaxanthin enhanced energy production leading to a longer running time during treadmill exercise (27).

Under physiological conditions, the maintenance of skeletal muscle mass depends on the balance between muscle protein synthesis and muscle protein degradation (64). Muscle atrophy occurs when the rate of protein degradation outweighs the rate of protein synthesis (65). The suggested signal transduction involved in muscle protein synthesis and degradation includes the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signalling and Forkhead Box O (FoxO) transcription factor. The activation of PI3K/Akt/mTOR pathway is modulated by the interaction of insulin growth factor-1 (IGF-1) and insulin with their respective tyrosine kinase receptors. The activated PI3K/Akt eventually phosphorylates mTOR and its downstream factor,

p70 ribosomal protein S6 kinase (P70S6K) to promote protein synthesis (66,67). The mixture of three antioxidants (astaxanthin,  $\beta$ -carotene and resveratrol) was shown to have greater efficacy than each antioxidant respectively in increasing relative soleus weight. This outcome was mediated through the increased phosphorylation of mTOR and its downstream factor (P70S6K) in male mice with muscle atrophy (29). FoxO transcription factors play a role in the catabolic pathway in skeletal muscle. FoxO is phosphorylated (inhibited) by Akt, thus the genes responsible for muscle atrophy cannot be transcribed (68). In the study performed by Kanazashi *et al* (32), it was noted that hindlimb unloading induced muscle atrophy in the rats by activating the ubiquitin-proteasome pathway through reduced phosphorylation (activation) of Forkhead box class O 3a (FoxO3a). It is also evident that protein degradation during muscle disuse is associated with activation of the ubiquitin-proteasome proteolytic pathway, resulting in increased ubiquitinated protein expression. Muscle atrophy induced by hindlimb unloading was reversed by the combined intervention of astaxanthin and electrical stimulation via increased phosphorylation (inhibition) of FoxO3a (32). In addition, it has been reported that the induction of oxidative stress stimulated protein degradation by upregulating calpain (a proteolytic enzyme act upstream of the ubiquitin-proteasome proteolytic pathway) (69). It was revealed that dietary astaxanthin intake protected against disuse muscle atrophy in rats, which was partly due to the reduction of oxidative stress, calpain and ubiquitin expression (38).

Another mechanism of action that explains the positive effects of astaxanthin in suppressing disuse skeletal muscle atrophy involves the inhibition of myonuclear apoptosis. Apoptosis of myonuclei contributes to the loss of muscle mass. Previous work by Yoshihara *et al* (33) indicated that dietary astaxanthin supplementation prevented the increase of apoptotic nuclei in soleus muscle [indicated by decreased

number of terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)-positive nuclei]. Satellite cells (also known as skeletal muscle stem cells) are the precursors of skeletal muscle cells required for muscle mass maintenance and muscle regeneration following muscle atrophy (70). Previous studies have demonstrated the alterations of satellite cell activity and density by muscle catabolic conditions, such as disuse and ageing (71). Indeed, Yoshihara and co-authors (34) also revealed that the protection against disuse muscle atrophy exerted by astaxanthin might be due to the increase in satellite cell numbers.

The capillary number in skeletal muscle is proportionate with muscle loading and activity levels. For instance, exercise and functional overload promote capillary growth (72) whereas unloading and immobilization result in capillary regression (73). The regression of the capillary network during low level muscle loading and activity is often attributed to an increase in oxidative injury (11). Kanazashi *et al* (30,31) performed two studies to assess the effects of astaxanthin on skeletal muscle capillaries. In these studies, they reported that hindlimb unloading induced an overproduction of ROS, resulting in capillary regression and muscle atrophy in the animals. Upon astaxanthin intervention, the decreases in angiogenic factors [such as vascular endothelial growth factor (VEGF), hypoxia inducible factor-1 alpha (HIF-1 $\alpha$ ), FMS-like tyrosine kinase 1 (Flt-1), kinase insert domain-containing receptor (KDR), angiopoietin 1 (ANG-1) and tyrosine kinase with Ig and EGF homology domains 2 (Tie-2)] caused by hindlimb unloading were counteracted (30). The subsequent study revealed that hindlimb unloading decreased PGC-1 $\alpha$ , VEGF and succinate dehydrogenase (SDH) activity, which contributed to the detrimental effects on morphology and number of capillary networks in rat soleus muscle. Oral astaxanthin administration maintained the capillary network by increasing PGC-1 $\alpha$ , VEGF and SDH activity near values of animals with sarcopenia (31).

## 6. Perspectives and conclusion

In the present review, the role of astaxanthin on skeletal muscle was examined in two major conditions: Physical exercise and muscle atrophy. Though the direct beneficial effects of astaxanthin on skeletal muscle were marginal in certain studies, astaxanthin was shown to be a potentially effective agent to enhance skeletal muscle performance and counteract the detrimental effects of skeletal muscle disuse. The mechanisms of action of astaxanthin may be attributed to its potential to prevent oxidative stress, increase energy production in mitochondria, regulate the anabolic (regeneration) and catabolic (proteolysis) processes of skeletal muscle, suppress programmed cell death of the myonucleus and activate associated angiogenic pathways to maximize capillary network (Fig. 1). Among these molecular mechanisms, oxidative stress appears to be the common factor that ultimately causes stepwise escalation to the onset and progression of sarcopenia.

Several limitations of the currently available studies need to be addressed. Firstly, the evidence is largely preliminary and suggestive of the potential of astaxanthin in the management of sarcopenia. Much effort should be paid on further investigations to validate the clinical use of astaxanthin. Secondly,

the induction of oxidative stress in skeletal muscle has a direct mechanistic link with chronic state of low-grade inflammation during disuse muscle atrophy (50). Despite exhibiting anti-oxidative properties, astaxanthin has been reported to be useful for improving chronic inflammation (24,74). Therefore, investigation of the anti-inflammatory properties of astaxanthin during exercise or skeletal muscle atrophy may be a beneficial area of research. Thirdly, the test formulation provided in certain studies was a mixture of astaxanthin with other antioxidants. The positive health outcomes of astaxanthin alone could not be concluded as the effects might be derived from other antioxidative agents. As a combination of astaxanthin with other interventions may show greater efficacy than astaxanthin alone in promoting skeletal muscle health and performance astaxanthin may be beneficial when used clinically in conjunction with other interventions, such as exercise, hormonal and nutritional intervention to improve muscle health.

## Acknowledgements

Not applicable.

## Funding

This study was supported by grants from the Universiti Kebangsaan Malaysia and Ministry of Education, Malaysia (grant nos. MI-2019-006 and FRGS/1/2018/SKK10/UKM/03/1).

## Availability of data and materials

Not applicable.

## Authors' contributions

SKW performed the literature search and drafted the manuscript. SIN and KYC provided critical review for the manuscript. KYC gave final approval for the publication of this manuscript. All authors read and approved the final manuscript.

## Ethics approval and consent to participate

Not applicable.

## Patient consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## References

1. Santilli V, Bernetti A, Mangone M and Paoloni M: Clinical definition of sarcopenia. *Clin Cases Miner Bone Metab* 11: 177-180, 2014.
2. Trajanoska K, Schoufour JD, Darweesh SK, Benz E, Medina-Gomez C, Alferink LJ, Lahousse L, Brusselle G, Stricker B, Darwish Murad S, *et al*: Sarcopenia and its clinical correlates in the general population: The rotterdam study. *J Bone Miner Res* 33: 1209-1218, 2018.

3. Beaudart C, Rizzoli R, Bruyère O, Reginster JY and Biver E: Sarcopenia: Burden and challenges for public health. *Arch Public Health* 72: 45-45, 2014.
4. Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B and Heshmat R: Prevalence of sarcopenia in the world: A systematic review and meta-analysis of general population studies. *J Diabetes Metab Disord* 16: 21-21, 2017.
5. Goates S, Du K, Arensberg MB, Gaillard T, Guralnik J and Pereira SL: Economic impact of hospitalizations in US adults with sarcopenia. *J Frailty Aging* 8: 93-99, 2019.
6. World Population Ageing: World Population Ageing 2017. United Nations New York, 2017.
7. Kwak JY and Kwon KS: Pharmacological interventions for treatment of sarcopenia: Current status of drug development for sarcopenia. *Ann Geriatr Med Res* 23: 98-104, 2019.
8. Aoi W and Sakuma K: Oxidative stress and skeletal muscle dysfunction with aging. *Curr Aging Sci* 4: 101-109, 2011.
9. Londuhe P and Guttridge DC: Inflammation induced loss of skeletal muscle. *Bone* 80: 131-142, 2015.
10. Andreux PA, van Diemen MPJ, Heezen MR, Auwerx J, Rinsch C, Groeneveld GJ and Singh A: Mitochondrial function is impaired in the skeletal muscle of pre-frail elderly. *Sci Rep* 8: 8548, 2018.
11. Fujino H, Kondo H, Nagatomo F and Ishihara A: Capillary growth and regression in skeletal muscle. *J Phys Fit Sports Med* 3: 483-491, 2014.
12. Lee SP, Mar GY and Ng LT: Effects of tocotrienol-rich fraction on exercise endurance capacity and oxidative stress in forced swimming rats. *Eur J Appl Physiol* 107: 587-595, 2009.
13. Servais S, Letexier D, Favier R, Duchamp C and Desplanches D: Prevention of unloading-induced atrophy by vitamin E supplementation: Links between oxidative stress and soleus muscle proteolysis? *Free Radic Biol Med* 42: 627-635, 2007.
14. Higuera-Ciapara I, Felix-Valenzuela L and Goycoolea FM: Astaxanthin: A review of its chemistry and applications. *Crit Rev Food Sci Nutr* 46: 185-196, 2006.
15. Dose J, Matsugo S, Yokokawa H, Koshida Y, Okazaki S, Seidel U, Eggersdorfer M, Rimbach G and Esatbeyoglu T: Free radical scavenging and cellular antioxidant properties of astaxanthin. *Int J Mol Sci* 17: 103, 2016.
16. Park JS, Chyun JH, Kim YK, Line LL and Chew BP: Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. *Nutr Metab* 7: 18-18, 2010.
17. McCall B, McPartland CK, Moore R, Frank-Kamenetskii A and Booth BW: Effects of astaxanthin on the proliferation and migration of breast cancer cells in vitro. *Antioxidants* 7: 135, 2018.
18. Sila A, Ghlissi Z, Kamoun Z, Makni M, Nasri M, Bougatef A and Sahnoun Z: Astaxanthin from shrimp by-products ameliorates nephropathy in diabetic rats. *Eur J Nutr* 54: 301-307, 2015.
19. Kang H and Kim H: Astaxanthin and  $\beta$ -carotene in *Helicobacter pylori*-induced Gastric Inflammation: A mini-review on action mechanisms. *J Cancer Prev* 22: 57-61, 2017.
20. Rao AR, Sarada R, Shylaja MD and Ravishankar GA: Evaluation of hepatoprotective and antioxidant activity of astaxanthin and astaxanthin esters from microalgae-*Haematococcus pluvialis*. *J Food Sci Tech* 52: 6703-6710, 2015.
21. Feng Y, Chu A, Luo Q, Wu M, Shi X and Chen Y: The protective effect of astaxanthin on cognitive function via inhibition of oxidative stress and inflammation in the brains of chronic T2DM Rats. *Front Pharmacol* 9: 748, 2018.
22. Fassett RG and Coombes JS: Astaxanthin: A potential therapeutic agent in cardiovascular disease. *Mar Drugs* 9: 447-465, 2011.
23. Hashimoto H, Arai K, Hayashi S, Okamoto H, Takahashi J, Chikuda M and Obara Y: Effects of astaxanthin on antioxidation in human aqueous humor. *J Clin Biochem Nutr* 53: 1-7, 2013.
24. Davinelli S, Nielsen ME and Scapagnini G: Astaxanthin in skin health, repair, and disease: A comprehensive review. *Nutrients* 10: 522, 2018.
25. Brown DR, Gough LA, Deb SK, Sparks SA and McNaughton LR: Astaxanthin in exercise metabolism, performance and recovery: A review. *Front Nutr* 4: 76, 2017.
26. Yu T, Dohl J, Chen Y, Gasier HG and Deuster PA: Astaxanthin but not quercetin preserves mitochondrial integrity and function, ameliorates oxidative stress, and reduces heat-induced skeletal muscle injury. *J Cell Physiol* 234: 13292-13302, 2019.
27. Aoi W, Maoka T, Abe R, Fujishita M and Tominaga K: Comparison of the effect of non-esterified and esterified astaxanthins on endurance performance in mice. *J Clin Biochem Nutr* 62: 161-166, 2018.
28. Polotow TG, Vardaris CV, Mihaliuc AR, Gonçalves MS, Pereira B, Ganini D and Barros MP: Astaxanthin supplementation delays physical exhaustion and prevents redox imbalances in plasma and soleus muscles of Wistar rats. *Nutrients* 6: 5819-5838, 2014.
29. Kawamura A, Aoi W, Abe R, Kobayashi Y, Wada S, Kuwahata M and Higashi A: Combined intake of astaxanthin,  $\beta$ -carotene, and resveratrol elevates protein synthesis during muscle hypertrophy in mice. *Nutrition* 69: 110561, 2019.
30. Kanazashi M, Okumura Y, Al-Nassan S, Murakami S, Kondo H, Nagatomo F, Fujita N, Ishihara A, Roy RR and Fujino H: Protective effects of astaxanthin on capillary regression in atrophied soleus muscle of rats. *Acta Physiol* 207: 405-415, 2013.
31. Kanazashi M, Tanaka M, Murakami S, Kondo H, Nagatomo F, Ishihara A, Roy RR and Fujino H: Amelioration of capillary regression and atrophy of the soleus muscle in hindlimb-unloaded rats by astaxanthin supplementation and intermittent loading. *Exp Physiol* 99: 1065-1077, 2014.
32. Kanazashi M, Tanaka M, Nakanishi R, Maeshige N and Fujino H: Effects of astaxanthin supplementation and electrical stimulation on muscle atrophy and decreased oxidative capacity in soleus muscle during hindlimb unloading in rats. *J Physiol Sci* 69: 757-767, 2019.
33. Yoshihara T, Yamamoto Y, Shibaguchi T, Miyaji N, Kakigi R, Naito H, Goto K, Ohmori D, Yoshioka T and Sugiura T: Dietary astaxanthin supplementation attenuates disuse-induced muscle atrophy and myonuclear apoptosis in the rat soleus muscle. *J Physiol Sci* 67: 181-190, 2017.
34. Yoshihara T, Sugiura T, Miyaji N, Yamamoto Y, Shibaguchi T, Kakigi R, Naito H, Goto K, Ohmori D and Yoshioka T: Effect of a combination of astaxanthin supplementation, heat stress, and intermittent reloading on satellite cells during disuse muscle atrophy. *J Zhejiang Univ Sci B* 19: 844-852, 2018.
35. Wang F, Zhang QB, Zhou Y, Chen S, Huang PP, Liu Y and Xu YH: The mechanisms and treatments of muscular pathological changes in immobilization-induced joint contracture: A literature review. *Chin J Traumatol* 22: 93-98, 2019.
36. Frimel TN, Kapadia F, Gaidosh GS, Li Y, Walter GA and Vandenborne K: A model of muscle atrophy using cast immobilization in mice. *Muscle Nerve* 32: 672-674, 2005.
37. Morey-Holton ER and Globus RK: Hindlimb unloading rodent model: Technical aspects. *J Appl Physiol* (1985) 92: 1367-1377, 2002.
38. Shibaguchi T, Yamaguchi Y, Miyaji N, Yoshihara T, Naito H, Goto K, Ohmori D, Yoshioka T and Sugiura T: Astaxanthin intake attenuates muscle atrophy caused by immobilization in rats. *Physiol Rep* 4: e12885, 2016.
39. Maezawa T, Tanaka M, Kanazashi M, Maeshige N, Kondo H, Ishihara A and Fujino H: Astaxanthin supplementation attenuates immobilization-induced skeletal muscle fibrosis via suppression of oxidative stress. *J Physiol Sci* 67: 603-611, 2017.
40. Nishida Y, Nawaz A, Kado T, Takikawa A, Igarashi Y, Onogi Y, Wada T, Sasaoka T, Yamamoto S, Sasahara M, *et al*: Astaxanthin stimulates mitochondrial biogenesis in insulin resistant muscle via activation of AMPK pathway. *J Cachexia Sarcopenia Muscle* 11: 241-258, 2020.
41. Inoue H, Shimamoto S, Takahashi H, Kawashima Y, Wataru S, Ijiri D and Ohtsuka A: Effects of astaxanthin-rich dried cell powder from *Paracoccus carotinifaciens* on carotenoid composition and lipid peroxidation in skeletal muscle of broiler chickens under thermo-neutral or realistic high temperature conditions. *Anim Sci J* 90: 229-236, 2019.
42. Mancini RA and Hunt MC: Current research in meat color. *Meat Sci* 71: 100-121, 2005.
43. Zeferino CP, Komiyama CM, Pelícia VC, Fascina VB, Aoyagi MM, Coutinho LL, Sartori JR and Moura AS: Carcass and meat quality traits of chickens fed diets concurrently supplemented with vitamins C and E under constant heat stress. *Animal* 10: 163-171, 2016.
44. Bloomer RJ, Fry A, Schilling B, Chiu L, Hori N and Weiss L: Astaxanthin supplementation does not attenuate muscle injury following eccentric exercise in resistance-trained men. *Int J Sport Nutr Exerc Metab* 15: 401-412, 2005.
45. Djordjevic B, Baralic I, Kotur-Stevuljevic J, Stefanovic A, Ivanisevic J, Radivojevic N, Andjelkovic M and Dikic N: Effect of astaxanthin supplementation on muscle damage and oxidative stress markers in elite young soccer players. *J Sports Med Phys Fitness* 52: 382-392, 2012.
46. Liu SZ, Ali AS, Campbell MD, Kilroy K, Shankland EG, Roshanravan B, Marcinek DJ and Conley KE: Building strength, endurance, and mobility using an astaxanthin formulation with functional training in elderly. *J Cachexia Sarcopenia Muscle* 9: 826-833, 2018.

47. Takami M, Aoi W, Terajima H, Tanimura Y, Wada S and Higashi A: Effect of dietary antioxidant-rich foods combined with aerobic training on energy metabolism in healthy young men. *J Clin Biochem Nutr* 64: 79-85, 2019.
48. Scicchitano BM, Pelosi L, Sica G and Musarò A: The physiopathologic role of oxidative stress in skeletal muscle. *Mech Ageing Dev* 170: 37-44, 2018.
49. Brioché T and Lemoine-Morel S: Oxidative stress, sarcopenia, antioxidant strategies and exercise: Molecular aspects. *Curr Pharm Des* 22: 2664-2678, 2016.
50. Meng SJ and Yu LJ: Oxidative stress, molecular inflammation and sarcopenia. *Int J Mol Sci* 11: 1509-1526, 2010.
51. Sztretye M, Dienes B, Gönczi M, Czirájk T, Csernoch L, Dux L, Szentesi P and Keller-Pintér A: Astaxanthin: A potential mitochondrial-targeted antioxidant treatment in diseases and with aging. *Oxid Med Cell Longev* 3849692, 2019.
52. Aoi W, Naito Y, Sakuma K, Kuchide M, Tokuda H, Maoka T, Toyokuni S, Oka S, Yasuhara M and Yoshikawa T: Astaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice. *Antioxid Redox Signal* 5: 139-144, 2003.
53. Zhou Y, Baker JS, Chen X, Wang Y, Chen H, Davison GW and Yan X: High-dose astaxanthin supplementation suppresses antioxidant enzyme activity during moderate-intensity swimming training in mice. *Nutrients* 11, 1244, 2019.
54. Kurutas EB: The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: Current state. *Nutr J* 15: 71-71, 2016.
55. Vomund S, Schäfer A, Parnham MJ, Brüne B and von Knethen A: Nrf2, the master regulator of anti-oxidative responses. *Int J Mol Sci* 18: 2772, 2017.
56. Bellezza I, Giambanco I, Minelli A and Donato R: Nrf2-Keap1 signaling in oxidative and reductive stress. *Biochim Biophys Acta Mol Cell Res* 1865: 721-733, 2018.
57. Guo C, Sun L, Chen X and Zhang D: Oxidative stress, mitochondrial damage and neurodegenerative diseases. *Neural Regen Res* 8: 2003-2014, 2013.
58. Ren J, Pulakat L, Whaley-Connell A and Sowers JR: Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. *J Mol Med* 88: 993-1001, 2010.
59. Coen PM, Musci RV, Hinkley JM and Miller BF: Mitochondria as a target for mitigating Sarcopenia. *Front Physiol* 9: 1883, 2018.
60. Liang H and Ward WF: PGC-1 $\alpha$ : A key regulator of energy metabolism. *Adv Physiol Educ* 30: 145-151, 2006.
61. Litvinova L, Atochin DN, Fattakhov N, Vasilenko M, Zatolokin P and Kirienkova E: Nitric oxide and mitochondria in metabolic syndrome. *Front Physiol* 6: 20, 2015.
62. Austin S and St-Pierre J: PGC1  $\alpha$  and mitochondrial metabolism-emerging concepts and relevance in ageing and neurodegenerative disorders. *J Cell Sci* 125: 4963-4971, 2012.
63. Liu PH, Aoi W, Takami M, Terajima H, Tanimura Y, Naito Y, Itoh Y and Yoshikawa T: The astaxanthin-induced improvement in lipid metabolism during exercise is mediated by a PGC-1 $\alpha$  increase in skeletal muscle. *J Clin Biochem Nutr* 54: 86-89, 2014.
64. Gordon BS, Kelleher AR and Kimball SR: Regulation of muscle protein synthesis and the effects of catabolic states. *Int J Biochem Cell Biol* 45: 2147-2157, 2013.
65. Sandri M: Protein breakdown in muscle wasting: Role of autophagy-lysosome and ubiquitin-proteasome. *Int J Biochem Cell Biol* 45: 2121-2129, 2013.
66. Latres E, Amini AR, Amini AA, Griffiths J, Martin FJ, Wei Y, Lin HC, Yancopoulos GD and Glass DJ: Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. *J Biol Chem* 280: 2737-2744, 2005.
67. Ziaaldini MM, Marzetti E, Picca A and Murlasits Z: Biochemical pathways of sarcopenia and their modulation by physical exercise: A narrative review. *Front Med* 4: 167, 2017.
68. Sanchez AM, Candau RB and Bernardi H: FoxO transcription factors: Their roles in the maintenance of skeletal muscle homeostasis. *Cell Mol Life Sci* 71: 1657-1671, 2014.
69. Smuder AJ, Kavazis AN, Hudson MB, Nelson WB and Powers SK: Oxidation enhances myofibrillar protein degradation via calpain and caspase-3. *Free Radic Biol Med* 49: 1152-1160, 2010.
70. Dumont NA, Bentzinger CF, Sincennes MC and Rudnicki MA: Satellite cells and skeletal muscle regeneration. *Compr Physiol* 5: 1027-1059, 2015.
71. McKenna CF and Fry CS: Altered satellite cell dynamics accompany skeletal muscle atrophy during chronic illness, disuse, and aging. *Curr Opin Clin Nutr Metab Care* 20: 447-452, 2017.
72. Hoier B and Hellsten Y: Exercise-induced capillary growth in human skeletal muscle and the dynamics of VEGF. *Microcirculation* 21: 301-314, 2014.
73. Fujino H, Kohzuki H, Takeda I, Kiyooka T, Miyasaka T, Mohri S, Shimizu J and Kajiya F: Regression of capillary network in atrophied soleus muscle induced by hindlimb unweighting. *J Appl Physiol* 98: 1407-1413, 2005.
74. Miyachi M, Matsuno T, Asano K and Mataga I: Anti-inflammatory effects of astaxanthin in the human gingival keratinocyte line NDUSD-1. *J Clin Biochem Nutr* 56: 171-178, 2015.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.